# Neoadjuvant chemotherapy response prediction using pretreatment diffusion and contrast-enhanced magnetic resonance imaging with clinical variables

arXiv: https://arxiv.org/abs/2609.26105 · HTML: https://mlsanity.com/paper/2609.26105/

## Key facts

- No citing papers in the map yet (data through 14 Oct 2026).
- Builds on 2 of its 24 references that are in the map.
- First posted on arXiv 18 Aug 2026.

## Builds on (most cited first, 2 of 2)

- [Bridging 2D and 3D Segmentation Networks for Computation Efficient Volumetric Medical Image Segmentation: An Empirical Study of 2.5D Solutions](https://mlsanity.com/paper/2010.06163/) (2020)
- [Convolutional Restricted Boltzmann Machine Based-Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer](https://mlsanity.com/paper/1905.13312/) (2019)

## Abstract (arXiv)

Prediction of pathological complete response before neoadjuvant chemotherapy may facilitate more tailored therapeutic planning for breast cancer patients. This work proposes a deep-learning model for pretreatment data only, combining apparent diffusion coefficient maps, dynamic contrast-enhanced magnetic resonance imaging, and clinical variables. The study uses the public ACRIN 6698/I-SPY2 multicenter dataset. The architecture employs EfficientNet-B0 pretrained encoders for image feature extraction and late fusion with clinical information. Multiple clinical variables were evaluated, including age, race, histological type, HR/HER2 subtype, SBR grade, and maximum diameter. Only HR/HER2 subtype improved the average area under the receiver operating characteristic curve (AUC) and was retained in the final model. Using stratified five-fold cross-validation, standalone apparent diffusion coefficient maps achieved a mean AUC of 0.79, whereas dynamic contrast-enhanced magnetic resonance imaging achieved 0.74. Adding HR/HER2 subtype improved performance to 0.83 and 0.81, respectively. The final configuration, using both imaging modalities and HR/HER2 subtype, achieved an AUC of 0.86. These results support pretreatment multimodal learning for response prediction, although external validation is required before clinical use.